Revenue performance to improve, Low base to drive earnings We expect the companies under our pharmaceuticals coverage to report revenue growth of 17.2% in Q1FY20 with 15.7% growth in profitability, aided by low base with lower single digit price erosion. The US revenues are expected to deliver double digit growth due to favorable currency movement and moderate recovery in base business. In domestic market, better pricing growth and new launches are expected to drive growth in the domestic formulation space. Overall structural trends in the sector give us long-term comfort, based on overall earnings decline is expected to bottom out in the near term. Overall our pharma coverage would post Revenue/EBIDTA/PAT growth of...